Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment.
Advertisement
By Editor
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment.